Valenva manufactures COVID vac

8
Comment
Favorite

guardzzz
2022-01-21

Valenva manufactures COVID vaccines using$Dynavax(DVAX)$adjuvant CPG 1018!

VALN Stock Alert: 4 Things to Know About the Vaccine News Sending Valneva Soaring

Vaccine companies are all the rage as giants like Moderna(NASDAQ:MRNA) and Pfizer(NYSE:PFE) race to

VALN Stock Alert: 4 Things to Know About the Vaccine News Sending Valneva Soaring

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

Top
Latest

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":9004742357,"tweetId":"9004742357","gmtCreate":1642710599040,"gmtModify":1676533737584,"author":{"id":4092370164549630,"authorId":4092370164549630,"authorIdStr":"4092370164549630","name":"guardzzz","avatar":"https://static.tigerbbs.com/b4192924900e3dc15d244e68aea44b8d","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Valenva manufactures COVID vaccines using<a href=\"https://ttm.financial/S/DVAX\">$Dynavax(DVAX)$</a>adjuvant CPG 1018!&nbsp;</p></body></html>","htmlText":"<html><head></head><body><p>Valenva manufactures COVID vaccines using<a href=\"https://ttm.financial/S/DVAX\">$Dynavax(DVAX)$</a>adjuvant CPG 1018!&nbsp;</p></body></html>","text":"Valenva manufactures COVID vaccines using$Dynavax(DVAX)$adjuvant CPG 1018!","highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/9004742357","repostId":1101627626,"repostType":4,"repost":{"id":"1101627626","pubTimestamp":1642644772,"share":"https://www.laohu8.com/m/news/1101627626?lang=&edition=full","pubTime":"2022-01-20 10:12","market":"us","language":"en","title":"VALN Stock Alert: 4 Things to Know About the Vaccine News Sending Valneva Soaring","url":"https://stock-news.laohu8.com/highlight/detail?id=1101627626","media":"InvestorPlace","summary":"Vaccine companies are all the rage as giants like Moderna(NASDAQ:MRNA) and Pfizer(NYSE:PFE) race to ","content":"<html><head></head><body><p>Vaccine companies are all the rage as giants like <b>Moderna</b>(NASDAQ:<b><u>MRNA</u></b>) and <b>Pfizer</b>(NYSE:<b><u>PFE</u></b>) race to develop a vaccine for the omicron variant. While daily U.S. cases of Covid-19 are still elevated, the number of daily cases has started to fall. This is certainly great news for the world. However, a lesser-known biotech company is adding to the good news today. That biotech company is <b>Valneva</b>(NASDAQ:<b><u>VALN</u></b>).</p><p>Today, Valneva reported encouraging results from its preliminary study. The French biotech company reported that three doses of its inactivated vaccine candidate demonstrated neutralizing abilities against the omicron variant. In addition, 100% of the 30 serum samples tested presented neutralizing antibodies against the “ancestral virus and Delta variant,” while 87% of the samples presented neutralizing antibodies against the omicron variant.</p><p>Put simply,inactivated vaccines involve using an inactive, or dead, version of the virus to introduce the body to the virus. Once the inactive virus is in a human, the human’s immune system can recognize the virus in future interactions and more readily defend against it. Inactive vaccines don’t provide as much immunity as live vaccines, so several doses, or booster shots, over time may be needed.</p><p>So, what else should investors know about Valneva’s exciting vaccine candidate? Let’s jump right in.</p><p><b>4 Things to Know About the Positive Vaccine News</b></p><ol><li>Valneva states that it expects to receive potential approvals for its vaccine in the first three months of 2022. The vaccine maker is also providing data to several regulators in the United Kingdom and Bahrain, as well as to the European Medicines Agency (EMA)</li><li>Last November, Valneva signed aconditional contractwith the European Commission to supply up to 60 million doses of its vaccine candidate over two years. The conditional part of the contract states that Valneva must receive approval from the EMA before making any deliveries. If approved, Valneva expects to deliver vaccines starting in April.</li><li>Valneva has also signed a similar contract with the Bahraini National Health Regulatory Agency (NHRA). If approved, Valneva expects to start delivering vaccines in the first quarter of 2022.</li><li>Even with today’s 40%-plus gain, shares of VALN stock are still down 15% year to date. Investors will want to stay up to date on regulatory approvals and trial results as Valneva seeks to neutralize the omicron variant.</li></ol></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>VALN Stock Alert: 4 Things to Know About the Vaccine News Sending Valneva Soaring</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVALN Stock Alert: 4 Things to Know About the Vaccine News Sending Valneva Soaring\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-20 10:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/01/valn-stock-alert-4-things-to-know-about-the-vaccine-news-sending-valneva-soaring/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vaccine companies are all the rage as giants like Moderna(NASDAQ:MRNA) and Pfizer(NYSE:PFE) race to develop a vaccine for the omicron variant. While daily U.S. cases of Covid-19 are still elevated, ...</p>\n\n<a href=\"https://investorplace.com/2022/01/valn-stock-alert-4-things-to-know-about-the-vaccine-news-sending-valneva-soaring/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VALN":"Valneva SE"},"source_url":"https://investorplace.com/2022/01/valn-stock-alert-4-things-to-know-about-the-vaccine-news-sending-valneva-soaring/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101627626","content_text":"Vaccine companies are all the rage as giants like Moderna(NASDAQ:MRNA) and Pfizer(NYSE:PFE) race to develop a vaccine for the omicron variant. While daily U.S. cases of Covid-19 are still elevated, the number of daily cases has started to fall. This is certainly great news for the world. However, a lesser-known biotech company is adding to the good news today. That biotech company is Valneva(NASDAQ:VALN).Today, Valneva reported encouraging results from its preliminary study. The French biotech company reported that three doses of its inactivated vaccine candidate demonstrated neutralizing abilities against the omicron variant. In addition, 100% of the 30 serum samples tested presented neutralizing antibodies against the “ancestral virus and Delta variant,” while 87% of the samples presented neutralizing antibodies against the omicron variant.Put simply,inactivated vaccines involve using an inactive, or dead, version of the virus to introduce the body to the virus. Once the inactive virus is in a human, the human’s immune system can recognize the virus in future interactions and more readily defend against it. Inactive vaccines don’t provide as much immunity as live vaccines, so several doses, or booster shots, over time may be needed.So, what else should investors know about Valneva’s exciting vaccine candidate? Let’s jump right in.4 Things to Know About the Positive Vaccine NewsValneva states that it expects to receive potential approvals for its vaccine in the first three months of 2022. The vaccine maker is also providing data to several regulators in the United Kingdom and Bahrain, as well as to the European Medicines Agency (EMA)Last November, Valneva signed aconditional contractwith the European Commission to supply up to 60 million doses of its vaccine candidate over two years. The conditional part of the contract states that Valneva must receive approval from the EMA before making any deliveries. If approved, Valneva expects to deliver vaccines starting in April.Valneva has also signed a similar contract with the Bahraini National Health Regulatory Agency (NHRA). If approved, Valneva expects to start delivering vaccines in the first quarter of 2022.Even with today’s 40%-plus gain, shares of VALN stock are still down 15% year to date. Investors will want to stay up to date on regulatory approvals and trial results as Valneva seeks to neutralize the omicron variant.","news_type":1},"isVote":1,"tweetType":1,"viewCount":293,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["DVAX"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":68,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}